1-(2-Methoxyphenoxy)butan-2-ol | 56220-29-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(2-Methoxyphenoxy)butan-2-ol
• CAS: 56220-29-2
• 化学式: C₁₁H₁₆O₃
• 分子量: 196.246
• InChiKey: WYSCQDIKGHVGMR-UHFFFAOYSA-N

物化性质

• 沸点：
  147 °C(Press: 9 Torr)
• 密度：
  1.061±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-Methoxyphenoxy)butan-2-ol 、 三甲基乙酰氯 在 吡啶 作用下， 生成 2,2-Dimethyl-propionic acid 1-(2-methoxy-phenoxymethyl)-propyl ester
  参考文献：
  名称：

  .beta.-Phenoxy or substituted phenoxy ethanol compounds

  摘要：

  新型的.beta.-苯氧基或取代苯氧基-乙醇化合物或其酯，其表达式如下：##STR1##其中R.sup.1是氢原子或烷基，R.sup.2是氢原子或取代基，Y是--OH基团或基团##STR2##，R.sup.3是烷基，n是1到3的整数。这些化合物具有幼虫激素活性，可用于激素杀虫和增加蚕茧产量。

  公开号：

  US04016186A1
• 作为产物：
  描述：

  1,2-环氧丁烷 生成 1-(2-Methoxyphenoxy)butan-2-ol
  参考文献：
  名称：

  EGGENSPERGER, HEINZ;DIEHL, KARL-HEINZ;MOHR, MICHAEL;RACKUR, HALMUT;BEILFU+

  摘要：

  DOI：

文献信息

• Process for the Preparation of Ranolazine
  申请人：Shi Mingfeng

  公开号：US20130090475A1

  公开（公告）日：2013-04-11

  A process for the preparation of ranolazine comprises the step of condensing N-(2,6-dimethylphenyl)-1-piperazinyl acetamide with a compound of formula (I) to obtain ranolazine, in which X is chlorine or bromine Ranolazine is prepared by condensing ring-opening halide which replaces epoxide in this process.

  制备拉诺利嗪的方法包括将N-(2,6-二甲基苯基)-1-哌嗪基乙酰胺与式(I)的化合物缩合步骤，以获得拉诺利嗪，其中X为氯或溴。拉诺利嗪是通过在该过程中用取代环氧化物的环开口卤代物缩合制备的。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND INFLAMMATION<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES NEUROLOGIQUES ET D'UNE INFLAMMATION
  申请人：KANDULA MAHESH

  公开号：WO2014115098A1

  公开（公告）日：2014-07-31

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological diseases and inflammation, a neurological disease, allergy, respiratory diseases or inflammatory disorder may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle disorders, neurological diseases and inflammation, spasticity, neuropathic pain, fibromyalgia, Parkinson's disease, allergy, asthma, chronic obstructive pulmonary disease, allergic rhinitis, headache, chronic pain, sub-chronic pain and local pain or its associated complications.

  该发明涉及具有化学式I或其药用可接受的盐的化合物，以及其多型、溶剂合物、对映体、立体异构体和水合物。包括化学式I化合物的有效量的药物组合物；以及用于治疗或预防神经系统疾病和炎症、神经系统疾病、过敏、呼吸系统疾病或炎症性疾病的方法，可以制备用于口服、颊内、直肠、局部、经皮、经粘膜、静脉内、肠道、糖浆或注射的药物组合物。这些组合物可以用于治疗肌肉障碍、神经系统疾病和炎症、痉挛、神经病性疼痛、纤维肌痛、帕金森病、过敏、哮喘、慢性阻塞性肺病、过敏性鼻炎、头痛、慢性疼痛、亚慢性疼痛和局部疼痛或其相关并发症的治疗。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150080370A1

  公开（公告）日：2015-03-19

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及的化合物是钠通道抑制剂，用于治疗各种疾病状态，包括心血管疾病和糖尿病。在特定实施例中，化合物的结构由公式I给出：其中R1，R2，R3，R4和R5如本文所述，涉及该化合物的制备和使用方法以及包含该化合物的制药组合物。
• COMBINED ADMINISTRATION OF BENZONATATE AND GUAIFENESIN
  申请人：Heck Thomas

  公开号：US20080176955A1

  公开（公告）日：2008-07-24

  Pharmaceutical compositions are provided containing a combination of benzonatate and guaifenesin, or pharmaceutically acceptable salts thereof. Methods of using compositions comprising benzonatate and guaifenesin, or pharmaceutically acceptable salts thereof, provide relief from cough, pulmonary congestion or both. The compositions and methods provide relief to opiate-sensitive individuals, in particular, as well as to infants and other pediatric patients.
• US8703759B2
  申请人：——

  公开号：US8703759B2

  公开（公告）日：2014-04-22